DCM
KDNY

Delpha Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Delpha Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-562
Closed -$21K – 1356
2017
Q4 		$21K Buy
+562
New +$24.5K 0.02% 761

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Delpha Capital Management's KDNY Position: Q1 2018 in Review

Delpha Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2018, closing a stake of 562 shares — an estimated $21K sold.

Delpha Capital Management first reported a position in KDNY in Q4 2017 and held it in 1 quarter. The position peaked at $21K in Q4 2017. 92 funds tracked by Wall St. Rank hold KDNY as of Q1 2018.

  • Delpha Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 562 Chinook Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $21K.
  • Delpha Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $21K in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.